Virus therapy of human cancers [2]

Melanoma Research

Volumn 13, Issue 4, 2003, Pages 431-432

  Sinkovics, J G ^a   Horvath, J C ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CISPLATIN; DACARBAZINE; IMMUNOGLOBULIN; MELANOMA VACCINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; VINBLASTINE; VIRUS ONCOLYSATE;

ADULT; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER THERAPY; CASE REPORT; CLINICAL TRIAL; HUMAN; HUMAN CELL; LETTER; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MELANOMA; MELANOMA CELL; NEWCASTLE DISEASE PARAMYXOVIRUS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TUMOR; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

CANCER VACCINES; FATAL OUTCOME; HUMANS; INJECTIONS, INTRALESIONAL; INTERFERON ALFA-2B; MALE; MELANOMA; MIDDLE AGED; NEWCASTLE DISEASE VIRUS; SKIN NEOPLASMS; TREATMENT FAILURE; VIRAL VACCINES;

EID: 0042367495     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200308000-00015     Document Type: Letter

References (20)

1. Sinkovics J, Horvath C. New developments in the virus therapy of cancer: a historical review. Intervirology 1993; 36:193-214.
2. Sabin A. Comments. Texas Rep Biol Med 1957; 15:151-153.
3. Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancer. J Clin Oncol 2002; 20:2251-2266.
4. Bergsland EK, Venook AP. Shedding old paradigms: developing viruses to treat cancer. J Clin Oncol 2002; 20:2220-2222.
5. Gilewski TA, Dang C, Surbone A and Norton L. Cytokinetics. In: Holland-Frei Cancer Medicine, 5th edn. London: BC Decker Inc Hamilton; 2000, pp. 511-538.
6. Phuangsab A, Lorence RM, Reichard KW, et al. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett 2001; 22:27-36.
7. Schirrmacher V, Griesbach A, Ahlert T. Antitumor effects of Newcastle disease virus in vivo: local versus systemic effects. Int J Oncol 2001; 18:945-952.
8. Sinkovics JG, Horvath JC. Vaccination against human cancers. Int J Oncol 2000; 16:81-96.
9. Horvath JC, Horvath E, Sinkovics JG, et al. Human melanoma cells eliminate autologous host lymphocytes and escape apoptotic death by utilizing the FasL→FasR system as an autocrine growth loop. Proc 89th Annu Meet Am Assoc Cancer Res 1998; 39:584 Abstract 2371.
10. Han D, Pottin-Clemenceau C, Imro MA, et al. IL-2 triggers a tumor progression process in a melanoma cell line MELP derived from a patient whose metastasis increased in size during IL-2/IFN alpha biotherapy. Oncogene 1996; 12:1015-1023.
11. Goillot E, Combaret V, Ladenstein R, et al. Tumor necrosis factor as an autocrine growth factor for neuroblastoma. Cancer Res 1992; 52:3194-3200.
12. Tong LJ, Yamaguchi N, Kita M, Imanishi J. Enhancement of the growth of human osteosarcoma cells by human interferon gamma. Cell Struct Funct 1992; 17:257-261.
13. Lorence RM, Rood PA, Kelley KW. Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor alpha and augmentation of its cytotoxicity. J Natl Cancer Inst 1988; 80:1305-1312.
14. Sinkovics JG, Howe CD. Superinfection of tumors with viruses. Experientia 1969; 25:733-734.
15. Bubenik J, Turano A. Enhancing effect on tumour growth of humoral antibodies against tumour-specific transplantation antigens in tumours by murine sarcoma virus (Harvey). Nature 1968; 220:928-930.
16. Sinkovics JG. Viral oncolysates as human tumor vaccines. Int Rev Immunol 1991; 7:259-287 (Erratum: Cassel's viral oncolysates always contained live NDV).
17. Ioannides CG, Platsoucas CD, O'Brian CA, et al. Viral oncolysates in cancer treatment: immunological mechanisms of action. Anticancer Res 1989; 9:535-544.
18. Cassel WA, Murray DR, Phillips HS. A phase II study on the postsurgical management of stage II malignant melanoma with Newcastle disease virus oncolysate. Cancer 1983; 52:856-860.
19. Cassel WA, Murray DR. A ten year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 1992; 9:169-171.
20. Nelson NJ. Scientific interest in Newcastle virus is reviving. J Natl Cancer Inst 1999; 91:1708-1710.